Last issue we made the case that fewer products lead to better skin. This week the question is what happens when the routine is finished and the patient still wants more.

"Botox or Sculptra?" comes up in primary care exam rooms far more often than referral patterns suggest, and the two products are not competitors.

Botulinum toxin type A has been FDA approved for glabellar lines since 2002 and remains one of the most common nonsurgical aesthetic procedures in the world.

Injectable poly-L-lactic acid (Sculptra) was approved in 2004 for HIV-associated facial lipoatrophy, expanded to nasolabial folds and other facial wrinkles in 2009, and approved for cheek wrinkles in April 2023. In the cheek trial (110 subjects), 94 percent still showed improvement at two years.

Botulinum toxin cleaves SNAP-25 at the neuromuscular junction, blocking acetylcholine release so the targeted muscle cannot contract fully. The effect reverses over three to four months. It treats lines caused by movement: frown lines, forehead lines, crow's feet.

Poly-L-lactic acid is a biodegradable polymer delivered as microparticles. It triggers a controlled foreign body response: macrophages and fibroblasts are recruited, the particles degrade, and new type I collagen is deposited in their place. It treats volume loss, laxity, and crepey texture. Results are gradual and can last up to two years per the label.

Neither one does the other's job.

A patient with deep static nasolabial folds who gets botulinum toxin sees little change, because those folds come from volume loss, not muscle activity.

A patient with dynamic frown lines who gets PLLA gets a fuller cheek and the same frown.

Botox Cosmetic is labeled for lines defined by muscle activity; Sculptra is labeled for folds and wrinkles assessed at rest.

Practical tip: Ask the patient to make the expression that bothers them. If the line disappears at rest, it is a muscle problem. If it stays, it is structural, and neuromodulator alone will disappoint.

Botulinum toxin is fast and temporary: onset within days, peak at about two weeks, duration up to four months.

PLLA is slow and long-lasting: collagen deposition builds over months, which is why treatment is a series of sessions spaced about a month or more apart.

Practical tip: Give patients one date to judge each product. Two weeks for botulinum toxin. Roughly three months after the final PLLA session.

Primary care often sees these first, especially when the patient went to a non-medical injector.

Botulinum toxin: Eyelid ptosis occurred in 3 percent of glabellar patients in the Botox Cosmetic label, brow ptosis in 2 percent with forehead treatment. Eyelid ptosis is usually unilateral, a few millimeters, worse late in the day, and resolves as the toxin wears off. Apraclonidine 0.5 percent drops, which stimulate Müller's muscle, are the standard temporizing measure.

PLLA: The characteristic persistent adverse event is the papule or nodule, appearing weeks to months after injection. Rates fall sharply with adequate reconstitution volume, deep placement, and post-injection massage, and consensus avoids the lips, nose, and periorbital area. Most nodules are non-inflammatory product collections rather than granulomas. The primary care point: a new firm subcutaneous facial nodule months after a "collagen treatment" is not automatically a cyst, a node, or a tumor. Ask about injectables before imaging or biopsy.

Practical tip: Post-injection eyelid drooping, new facial asymmetry, vision change, or skin discoloration along a vascular distribution needs same-day contact with the injector or dermatology. Non-inflammatory PLLA nodules can be referred routinely; painful, inflamed, or rapidly enlarging ones should be seen sooner.

Botulinum toxin: The label warns about neuromuscular disorders (myasthenia gravis, Lambert-Eaton syndrome, ALS) and potentiation by aminoglycosides. Infection at the site is a contraindication; elective treatment is deferred in pregnancy and lactation. The myth to retire: botulinum toxin products do not contain bovine protein, and dairy allergy is not a screening question. OnabotulinumtoxinA is stabilized with human albumin. True neutralizing antibody formation at aesthetic doses is rare; most "it stopped working" complaints are underdosing, targeting, or expectations.

PLLA: The label restricts use to immune-competent patients and has not been studied in patients with keloid history, active skin disease at the site, or pregnancy. Because it works through a foreign body response, patients who are immunosuppressed, have active autoimmune disease, or scar abnormally need a dermatology conversation before treatment. Unlike hyaluronic acid fillers, PLLA has no reversal agent.

Practical tip: Add three questions before any referral: neuromuscular disease, keloids or abnormal scarring, immunosuppression or autoimmune disease.

Patients do not think of aesthetic treatments as medical history. They are rarely on the medication list and often done outside a medical setting. Toxin diffusion can present as new facial asymmetry; PLLA can present as a subcutaneous mass; a patient treated by an unlicensed injector may have no documentation at all.

Practical tip: Ask at least yearly and with any new facial finding: "Have you had any injections in your face or neck in the past two years, including at a spa? What was it, and who did it?" Document product, date, and injector.

With multiple treatments over time, many patients report longer-lasting results.

That muscle atrophy we mentioned earlier means some people naturally extend to 5-6 month intervals.

We got you.

Take one of our modules

Here is our featured course for today!

“Becoming Better: The Groundbreaking Science of Personal Transformation” by Ryan Gottfredson

What if you could unlock a path to realizing true personal transformation; not just doing better, but becoming better?

Botox and Sculptra will keep arriving as a single question. The answer starts with which problem the patient actually has. Match the tool to the mechanism, give them one honest date to judge it by, and keep asking what has already been injected.

Until next time, stay curious and keep translating science into realistic hope.

See you next Thursday, DERM Community!

— The Derm for Primary Care Team